RESPIRATORY SYNCYTIAL VIRUS PREFUSION F (RSVPREF3) VACCINE

Course overview

RESPIRATORY SYNCYTIAL VIRUS (RSV) IS A PREVALENT RESPIRATORY PATHOGEN THAT PRIMARILY AFFECTS INFANTS, YOUNG CHILDREN, OLDER ADULTS, AND INDIVIDUALS WITH COMPROMISED IMMUNE SYSTEMS. RSV IS A SIGNIFICANT CAUSE OF ACUTE RESPIRATORY INFECTION, LOWER RESPIRATORY TRACT DISEASE (LRTD), CLINICAL COMPLICATIONS, AND DEATH IN OLDER ADULTS. THE RSVPREF3 VACCINE HAS BEEN DEVELOPED AS A RECOMBINANT SUBUNIT VACCINE THAT CONTAINS A PREFUSION FORM (PRE-F) OF THE RSV F GLYCOPROTEIN ANTIGEN (RSVPREF3) TO PREVENT LRTD. BY TARGETING THE PRE-F PROTEIN, THE VACCINE STIMULATES THE PRODUCTION OF NEUTRALIZING ANTIBODIES, ACTIVATES BOTH HUMORAL AND CELLULAR IMMUNE RESPONSES, AND PROMOTES THE FORMATION OF MEMORY B AND T CELLS. THIS ACTIVITY PROVIDES COMPREHENSIVE INFORMATION ON THE INDICATIONS, ADMINISTRATION, DOSAGE RECOMMENDATIONS, MECHANISM OF ACTION, MONITORING, ADVERSE REACTIONS, PRECAUTIONS, AND CONTRAINDICATIONS ASSOCIATED WITH RSVPREF3.